SL Science Holding Limited (NASDAQ:SLBT) ("SL Science" or the "Company"), a biotechnology company developing next-generation immune cell therapies, today announced its successful exhibition and participation at the 2026 World Congress of Basic and Clinical Pharmacology (WCP 2026) held at July 12-17, 2026 in Melbourne, Australia. Together with its esteemed academic and industry partners, the Company presented highly promising preclinical research on a novel treatment for glioblastoma (GBM), one of the most aggressive and difficult-to-treat forms of brain cancer.

The research showcased at the WCP 2026 exhibition is the result of a robust joint effort led by investigators at Taipei Medical University, in collaboration with SL Science, JY Biomedical Co., Ltd. ("JY BioMed") and HeXun Biosciences Co., Ltd.

Simplifying Complex Science for Real-World Impact

Glioblastoma is notoriously challenging to treat, often resisting conventional therapies such as surgery, radiation, and chemotherapy. Because tumors frequently return and build resistance, there is an urgent global need for innovative solutions. SL Science’s exhibition focused on harnessing gamma delta (γδ) T cells—a specialized subset of immune cells capable of identifying and attacking cancer cells without relying on the standard immune-matching processes that other therapies require.

The exhibited data revealed significant progress in overcoming tumor immune evasion. By delivering these specially expanded γδ T cells directly to the tumor site in preclinical models, researchers observed potent and efficient destruction of the brain cancer cells.

Key Exhibition Highlights

  • Complete Tumor Elimination: Direct administration of γδ T cells achieved complete eradication of the tumor by day 26 post-treatment at the highest dose tested (an 8:1 ratio of immune cells to cancer cells).
  • Dose-Dependent Success: The research demonstrated the feasibility and effectiveness of repeated direct-to-brain dosing, showing that the tumor-suppressing benefits scaled positively with the dosage.
  • Clean Safety Profile: Comprehensive health screens and blood panels confirmed that the treatment was well-tolerated in the study, showing no major safety concerns or adverse health effects.